Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2015-04-08 Share Issue/Capital Cha…
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
关于转让参股公司中科生物制药股份有限公司股份的公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement by Beijing SL Pharmaceutical Co., Ltd. regarding the transfer of its 18% equity stake in Zhongke Bio-Pharmaceutical Co., Ltd. to another investment entity. It details the transaction overview, parties involved, shareholding structure before and after the transfer, financial data of the target company, transaction terms, and the impact on the company. The document is an official announcement of a capital transaction involving share transfer, not a financial report, earnings release, or management discussion. It does not contain comprehensive financial statements or detailed financial analysis but focuses on the capital change event. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length is under 5,000 characters, but it is not merely announcing the publication of a report; it is the actual announcement of a share transfer transaction.
2015-04-08 Chinese
关于回购部分社会公众股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's repurchase of its own shares, detailing the number of shares bought back, prices, total amount paid, and the timeline for the buyback program. It references a previously approved share repurchase plan and provides an update on the execution status. The content is focused on share repurchase activity rather than financial results, management changes, or regulatory filings. Therefore, it fits the category of a Transaction in Own Shares (POS). The document length is short and contains specific transactional details, confirming it is not merely an announcement of a report but an actual update on share repurchase progress.
2015-04-01 Chinese
关于第二大股东新乡白鹭化纤集团有限责任公司部分股权质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the pledge of shares by a major shareholder (the second largest shareholder) of the company. It details the number of shares pledged, the dates of pledges, the banks involved, and the percentage of total shares pledged. There is no financial statement, earnings data, or management discussion. The document is a regulatory announcement about share pledging activity, which relates to capital structure but is not a financing update per se. It is not a report or presentation but a formal disclosure of share pledge status. This fits best under the category of Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other specific categories.
2015-03-30 Chinese
关于回购部分社会公众股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's repurchase of its own shares, detailing the number of shares bought back, prices, and total amount spent. It references a previously approved share repurchase plan and provides an update on the repurchase activity. The content is focused on share buyback activity rather than financial results, management changes, or regulatory filings. Therefore, it fits the category of Transaction in Own Shares (POS). The document length is short and contains specific transactional details, not just an announcement of a report, so it is not RPA or RNS.
2015-03-02 Chinese
2014年度业绩快报
Earnings Release Classification · 95% confidence The document is titled '2014 年度业绩快报' which translates to '2014 Annual Performance Express Report' or 'Annual Earnings Bulletin'. It contains preliminary financial data for the full year 2014, including revenue, profit, net income, earnings per share, and asset information. The document explicitly states that the data is preliminary, internally audited but not yet audited by an external accounting firm, and may differ from the final annual report. It also references the previous quarterly report and notes no difference in performance expectations. The document length is 1583 characters, which is relatively short and consistent with a brief earnings release rather than a full annual report. There is no indication that this is a full Annual Report (10-K) or a detailed Management Discussion & Analysis (MDA). It is not a report publication announcement since it contains actual financial data, not just a notice. Therefore, the document fits best as an Earnings Release (ER), which is an initial announcement of yearly financial results with key highlights only. FY 2014
2015-02-27 Chinese
关于回购部分社会公众股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement from Beijing SL Pharmaceutical Co., Ltd. regarding the progress of its share repurchase program. It details the number of shares repurchased, the price range, total amount paid, and the repurchase period. The document is short (600 characters) and focuses on the update of the company's buyback activity. It does not contain financial statements or detailed financial analysis, nor is it a report or presentation. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares.
2015-02-04 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.